[8-K] CalciMedica, Inc. Reports Material Event

Rhea-AI Filing Summary

CalciMedica, Inc. filed a Form 8-K reporting that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.

The report is signed by CEO A. Rachel Leheny, Ph.D.. The filing confirms the Nasdaq ticker CALC and that the registrant identified itself as an emerging growth company.

Positive

• Press release attached as Exhibit 99.1 announcing financial results for the quarter ended June 30, 2025.
• Inline XBRL cover page included as Exhibit 104, supporting structured data disclosure.
• Emerging growth company box is checked, consistent with the company's disclosure status.

Negative

• Information is furnished, not filed, so Item 2.02 and Exhibit 99.1 are not subject to certain Section 18 and Securities Act liabilities.
• The 8-K text does not include financial figures; the actual results must be read in the attached press release (Exhibit 99.1).

Insights

Financial Analyst

TL;DR: Routine earnings disclosure; press release furnished and attached, no financial details included in the 8-K text itself.

The Form 8-K notifies investors that CalciMedica issued a press release on August 12, 2025 announcing results for the quarter ended June 30, 2025, and attaches that release as Exhibit 99.1. The filing also includes an Inline XBRL cover page as Exhibit 104. Because the company expressly states the release is "furnished" rather than "filed," the 8-K limits statutory liabilities associated with filed disclosures. On balance this is a standard operational disclosure with neutral immediate market impact; material financial details would be found in the attached press release or subsequent filings.

Corporate Governance Expert

TL;DR: Governance-wise this is a routine, compliant disclosure; signature by the CEO and exhibit references are included.

The report is duly executed by CEO A. Rachel Leheny, Ph.D., and lists required exhibits (99.1 and 104). The emerging growth company checkbox is marked, which affects disclosure transition provisions. The filing's explicit statement that Item 2.02 and Exhibit 99.1 are furnished (not filed) is a common practice to manage statutory exposure. There are no governance red flags or departures from typical 8-K procedures in the text provided.

0001534133false00015341332025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

CalciMedica, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39538	45-2120079
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
505 Coast Boulevard South, Suite 307
La Jolla, California				92037
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-5500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CALC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2025 CalciMedica, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this report.

The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CalciMedica, Inc.
Date:	August 12, 2025	By:	/s/ A. Rachel Leheny, Ph. D.
		Name: Title:	A. Rachel Leheny, Ph. D. Chief Executive Officer

FAQ

What did CalciMedica (CALC) disclose in its Form 8-K filed August 12, 2025?

CalciMedica disclosed that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release included in the 8-K considered filed or furnished?

The company explicitly states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.

What exhibits were attached to CalciMedica's 8-K?

The filing lists Exhibit 99.1 (Press Release dated August 12, 2025) and Exhibit 104 (Cover Page Interactive Data File/Inline XBRL).

Who signed the Form 8-K for CalciMedica?

The Form 8-K is signed by A. Rachel Leheny, Ph.D., Chief Executive Officer.

Does the 8-K indicate CalciMedica is an emerging growth company?

Yes. The filing shows the emerging growth company box marked on the cover page.